Jefferies Reiterates Buy on NPS Pharmaceuticals (NPSP)

Jefferies is out with its report today on NPS Pharmaceuticals NPSP, reiterating Buy.

In a note to clients, Jefferies writes, "We view NPSP as a significantly de-risked story following 2nd confirmatory Gattex Ph3 data, but it's currently trading below the levels prior to the Ph3 data. From our expert discussions, we are bullish on NPSP at current valuation."

Jefferies has a $13 PT on NPSP.

Shares of NPSP closed Tuesday at $7.40.